Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Interstitial lung disease in rheumatoid arthritis patients

  Rheumatoid arthritis (RA) is best known for persistent joint inflammation, but its effects can extend to the lungs. Interstitial lung disease (ILD) is among the most serious extra-articular complications, involving inflammation and scarring in the tissue that supports oxygen exchange. It can develop before, alongside, or years after the diagnosis of arthritis.

  The clinical course varies widely. Some patients have mild, stable abnormalities detected incidentally, while others experience progressive pulmonary fibrosis, declining exercise capacity, and respiratory failure. Early recognition is therefore important, especially when respiratory symptoms may be mistaken for deconditioning, infection, or medication effects.

  For clinicians and delegates engaged with respiratory medicine through APSR and KATRD, RA-associated ILD illustrates the value of close cooperation between rheumatology, pulmonology, radiology, and primary care. A joint-focused assessment alone may overlook meaningful lung disease.

  Why rheumatoid arthritis can affect the lungs

  The same abnormal immune activity that targets synovial tissue can also affect the lung interstitium, pleura, airways, and pulmonary vasculature. In RA-associated ILD, repeated inflammatory injury may trigger remodeling and fibrosis. Smoking, older age, male sex, longstanding seropositive disease, and high concentrations of rheumatoid factor or anti-cyclic citrullinated peptide antibodies are recognized risk factors.

  Drug exposure can complicate the picture. Methotrexate and other disease-modifying antirheumatic drugs are sometimes considered when new respiratory symptoms appear, although distinguishing drug-related pneumonitis from RA-associated ILD, infection, or an unrelated lung condition requires careful clinical evaluation. Treatment decisions should be individualized rather than based on assumptions about one medicine.

  Patients may have no symptoms during the early phase. When symptoms occur, exertional breathlessness and a persistent dry cough are common. Fatigue and reduced stamina may be subtle but clinically meaningful, particularly in people whose joint pain already limits physical activity.

  Recognizing the main clinical patterns

  High-resolution computed tomography (HRCT) is central to defining the radiologic pattern. Usual interstitial pneumonia (UIP) is frequently reported in RA and may resemble the pattern seen in idiopathic pulmonary fibrosis. It is characterized by basal and peripheral reticulation, traction bronchiectasis, and, in established disease, honeycombing.

  Nonspecific interstitial pneumonia (NSIP) is another pattern and often shows more uniform ground-glass change and fine reticulation. Organizing pneumonia, airway-centered disease, and combined pulmonary fibrosis and emphysema can also occur. These patterns are not merely descriptive; they help inform prognosis, differential diagnosis, and treatment planning.

  Clinical symptoms should be interpreted alongside imaging and physiology. A patient with stable joint disease can still have progressing pulmonary fibrosis, while worsening breathlessness may reflect anemia, cardiac disease, pulmonary hypertension, infection, or muscle weakness rather than ILD alone. This is why a single test rarely provides a sufficient answer.

  Building a reliable diagnostic assessment

  Assessment generally begins with a detailed history covering breathlessness, cough, exercise tolerance, smoking, occupational exposures, reflux, infections, and previous medication changes. Examination may reveal fine “Velcro-like” inspiratory crackles, digital clubbing, low oxygen saturation, or signs of pulmonary hypertension, although their absence does not exclude disease.

  Pulmonary function testing usually includes forced vital capacity (FVC), total lung capacity, and diffusing capacity for carbon monoxide (DLCO). A reduced DLCO can be an early clue, but it may also reflect emphysema, anemia, or vascular disease. Six-minute walk testing and exertional oxygen measurements add practical information about functional limitation.

  HRCT should be interpreted by a radiologist familiar with diffuse parenchymal lung disease, ideally during a multidisciplinary discussion. Bronchoscopy or surgical lung biopsy is not routinely needed when the clinical context and HRCT pattern are characteristic. Infection testing, echocardiography, autoimmune review, and selected laboratory studies may be appropriate when competing diagnoses remain possible.

  Assessment area	What it can show	Why it matters
  Symptoms and examination	Breathlessness, cough, crackles, clubbing, low oxygen levels	Identifies clinical suspicion and severity
  Pulmonary function tests	Restriction, impaired gas transfer, change in FVC or DLCO	Tracks physiological progression
  HRCT	UIP, NSIP, organizing pneumonia, airway disease	Defines the structural lung pattern
  Six-minute walk test	Exercise limitation and oxygen desaturation	Measures functional impact
  Multidisciplinary review	Integrated interpretation of clinical, imaging, and laboratory data	Supports safer diagnosis and treatment

  Selecting treatment for the individual patient

  Management depends on disease extent, rate of progression, symptoms, comorbidities, and the dominant inflammatory or fibrotic features. Some patients require observation with structured monitoring, particularly when abnormalities are mild and stable. Others need active treatment because of worsening physiology, increasing fibrosis on imaging, or significant functional decline.

  Immunomodulatory therapy may be considered when inflammation is prominent or when there is another indication for controlling systemic RA activity. Commonly discussed options include mycophenolate, rituximab, abatacept, and selected glucocorticoid strategies, although evidence quality varies and treatment must account for infection risk, bone health, and other comorbidities.

  For progressive fibrotic disease, antifibrotic therapy such as nintedanib may be considered in appropriate cases. The decision should follow a careful review of progression and potential adverse effects. Patients and clinicians reviewing wider congress material can also consult the latest online update as part of the event’s broader digital resources, while treatment choices should remain grounded in specialist medical evaluation.

  Monitoring beyond the clinic visit

  Follow-up commonly combines symptoms, FVC, DLCO, oxygenation, exercise tolerance, and interval imaging. The timing depends on baseline severity and suspected trajectory; patients with active or progressive disease generally need closer review than those with stable, limited abnormalities. A meaningful decline in function should prompt reassessment rather than automatic continuation of the existing plan.

  Supportive care is equally important. Smoking cessation, vaccination, pulmonary rehabilitation, nutritional assessment, reflux management when clinically indicated, and supplemental oxygen for documented hypoxemia can improve safety and quality of life. Screening for pulmonary hypertension, sleep-disordered breathing, anxiety, and depression may identify additional causes of reduced function.

  A coordinated team can also review RA medication, infection prevention, and rehabilitation goals together. In advanced disease, early discussion of transplant referral or palliative approaches may be appropriate. These conversations are intended to improve planning and symptom control, not to signal that treatment has stopped.

  Practical priorities for shared care

  A consistent approach helps prevent both underdiagnosis and unnecessary testing. Useful priorities include:

  • Ask about exertional breathlessness and dry cough at routine RA reviews, even when joint symptoms are controlled.
  • Use baseline pulmonary function testing and HRCT selectively for patients with risk factors, symptoms, abnormal examination findings, or unexplained physiological changes.
  • Compare serial FVC, DLCO, oxygenation, exercise capacity, and imaging rather than relying on a single measurement.
  • Discuss suspected progression through a multidisciplinary team before changing immunosuppression or adding antifibrotic treatment.
  • Address vaccination, smoking, rehabilitation, occupational exposure, and medication safety as part of the lung-care plan.

  RA-associated ILD requires attention to both immune inflammation and irreversible fibrosis. Timely evaluation can clarify the diagnosis, identify progression earlier, and connect patients with therapies that address symptoms and preserve function. Respiratory and rheumatology teams can use congress-based education and multidisciplinary case review to strengthen pathways from screening to long-term care.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)